Additionally, we believe the results of LIBERATE-1 may provide clinical validation of our NanoPortal drug delivery technology to support a broader application of the technology in the treatment of chronic diseases. LIBERATE-1 will be a randomized investigation of the safety, tolerability and pharmacokinetic profile of the exenatide NanoPortal implant in obese or overweight patients
For more insight on research use only GLP-1s, please see my prior article here.
Microvasc Res 51(2):260272 Djonov V et al (2001) MMP-19: cellular localization of a novel metalloproteinase within normal breast tissue and mammary gland tumours
For context on how triple-agonist mechanisms compare to growth-hormone-related peptides in the research space, the tesamorelin vs sermorelin is a useful reference for understanding how different hormonal axes influence body composition
If an overdose is suspected, contact your local poison control center at 1-800-222-1222 or go to the nearest emergency room
This is the biology of obesity, not a personal failing